Tenaya Therapeutics (TNYA) will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy on Tuesday, December 17.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya Therapeutics doses first patient with TN-401 gene therapy
- Tenaya Therapeutics Reports Q3 2024 Progress and Financial Results
- Tenaya Therapeutics reports inducement grants under Nasdaq listing rule
- Tenaya Therapeutics price target raised to $18 from $16 at Canaccord
- Tenaya Therapeutics reports Q3 EPS (30c), consensus (37c)